Dimensional Fund Advisors LP Acquires 36,690 Shares of HilleVax, Inc. (NASDAQ:HLVX)

Dimensional Fund Advisors LP grew its holdings in shares of HilleVax, Inc. (NASDAQ:HLVX) by 31.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 152,602 shares of the company’s stock after acquiring an additional 36,690 shares during the quarter. Dimensional Fund Advisors LP owned about 0.31% of HilleVax worth $2,204,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in shares of HilleVax by 35.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company’s stock valued at $1,357,000 after acquiring an additional 24,410 shares during the last quarter. TD Asset Management Inc raised its holdings in shares of HilleVax by 53.9% during the 2nd quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after buying an additional 19,000 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of HilleVax by 27.0% during the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock valued at $617,000 after buying an additional 9,073 shares in the last quarter. Tidal Investments LLC purchased a new position in shares of HilleVax during the 1st quarter valued at about $207,000. Finally, EntryPoint Capital LLC purchased a new position in shares of HilleVax during the 1st quarter valued at about $80,000. Institutional investors own 86.42% of the company’s stock.

HilleVax Price Performance

Shares of HilleVax stock opened at $1.80 on Friday. The business’s 50 day simple moving average is $1.78 and its two-hundred day simple moving average is $8.00. The stock has a market capitalization of $89.50 million, a P/E ratio of -0.55 and a beta of 0.80. HilleVax, Inc. has a one year low of $1.55 and a one year high of $20.22.

HilleVax (NASDAQ:HLVX) last posted its earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). Sell-side analysts expect that HilleVax, Inc. will post -2.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HLVX. Leerink Partnrs cut HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. Guggenheim cut HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Stifel Nicolaus cut HilleVax from a “buy” rating to a “hold” rating and decreased their price objective for the company from $34.00 to $3.00 in a report on Tuesday, July 9th. Leerink Partners cut HilleVax from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a research note on Monday, August 12th. Six research analysts have rated the stock with a hold rating, According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.20.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.